Stockreport

Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF The company is now using its SKYLINE platform to test multiple monotherapy and combination regimens across six investigational agents, aiming to clarify how SPY001 and [Read more]